Senior Correspondent, London
Ben's Feed
Jul 24, 2014
Jul 24, 2014

Exclusive: Allegations of GSK corruption spread to Syria

LONDON (Reuters) – GlaxoSmithKline (GSK.L: Quote, Profile, Research, Stock Buzz) faces new allegations of corruption, this time in Syria, where the drugmaker and its distributor have been accused of paying bribes to secure business, according to a whistleblower’s email reviewed by Reuters.

Britain’s biggest drugmaker said on Thursday it was investigating the latest claims dating back to 2010, which were laid out in the email received by the company on July 18.

Jul 23, 2014
Jul 23, 2014

GSK warns on profits as weak lung drug sales hit

LONDON (Reuters) – GlaxoSmithKline cut its 2014 earnings outlook after sales fell by a worse-than-expected 13 percent in the second quarter as its all-important lung drugs struggled in the United States and a strong pound took a bite out of growth.

A run of weak quarters highlights the pressure on Chief Executive Andrew Witty, whose drive to reshape Britain’s biggest drugmaker has yet to deliver the hoped-for return to sustained revenue growth, following a lengthy period of patent expiries.

Jul 23, 2014

GSK cuts outlook as weak lung drug sales and strong pound hit

LONDON, July 23 (Reuters) – GlaxoSmithKline cut its
2014 outlook after sales fell by a worse-than-expected 13
percent in the second quarter as its all-important lung drugs
struggled in the United States and a strong pound took a bite
out of growth.

A run of weak quarters highlights the pressure on Chief
Executive Andrew Witty, whose drive to reshape Britain’s biggest
drugmaker has yet to deliver the hoped-for return to sustained
revenue growth, following a lengthy period of patent expiries.

Jul 22, 2014
Jul 22, 2014
Jul 22, 2014
Jul 11, 2014
Jul 11, 2014
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben